Recent Advances from Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma

Gastroenterology

Volumn 149, Issue 7, 2015, Pages 1700-1715

  Ohashi, Shinya ^a,b   Miyamoto, Shin'Ichi ^a   Kikuchi, Osamu ^a   Goto, Tomoyuki ^a   Amanuma, Yusuke ^a,b   Muto, Manabu ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Acetaldehyde; Aldehyde Dehydrogenase 2; Field Cancerization; Genetic Polymorphism; Squamous Differentiation

Indexed keywords

ACETALDEHYDE; ALCOHOL; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

ABLATION THERAPY; ADVANCED CANCER; BASIC RESEARCH; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CARCINOGENESIS; CHEMORADIOTHERAPY; CLINICAL RESEARCH; DNA POLYMORPHISM; ENDOSCOPIC SURGERY; ENDOSCOPY; EPIGENETICS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FANCONI ANEMIA; HUMAN; META ANALYSIS; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; PALLIATIVE THERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TOBACCO; WART VIRUS; ADVERSE EFFECTS; ANIMAL; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION; DRINKING BEHAVIOR; ESOPHAGEAL NEOPLASMS; GENETIC PREDISPOSITION; GENETICS; LIFESTYLE; METABOLISM; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; SMOKING; TREATMENT OUTCOME; VIROLOGY;

ALCOHOL DRINKING; ANIMALS; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIFE STYLE; NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SIGNAL TRANSDUCTION; SMOKING; TREATMENT OUTCOME;

EID: 84952898527     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.08.054     Document Type: Review

References (169)

1. A. Pennathur, M.K. Gibson, B.A. Jobe, and et al. Oesophageal carcinoma Lancet 381 2013 400 412
2. F. Kamangar, G.M. Dores, and W.F. Anderson Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J Clin Oncol 24 2006 2137 2150
3. J. Ferlay, I. Soerjomataram, R. Dikshit, and et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 2015 E359 E386
4. A.K. Rustgi, and H.B. El-Serag Esophageal carcinoma N Engl J Med 371 2014 2499 2509
5. A. Pickens, and M.B. Orringer Geographical distribution and racial disparity in esophageal cancer Ann Thorac Surg 76 2003 S1367 S1369
6. A. Jemal, F. Bray, M.M. Center, and et al. Global cancer statistics CA Cancer J Clin 61 2011 69 90
7. P.C. Enzinger, and R.J. Mayer Esophageal cancer N Engl J Med 349 2003 2241 2252
8. A. Pennathur, A. Farkas, A.M. Krasinskas, and et al. Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy Ann Thorac Surg 87 2009 1048 1054 discussion 1054-1055
9. M. Muto, T. Horimatsu, Y. Ezoe, and et al. Improving visualization techniques by narrow band imaging and magnification endoscopy J Gastroenterol Hepatol 24 2009 1333 1346
10. C. Bosetti, F. Levi, J. Ferlay, and et al. Trends in oesophageal cancer incidence and mortality in Europe Int J Cancer 122 2008 1118 1129
11. A. Prabhu, K.O. Obi, and J.H. Rubenstein The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: a meta-analysis Am J Gastroenterol 109 2014 822 827
12. B. Secretan, K. Straif, R. Baan, and et al. A review of human carcinogens - part E: tobacco, areca nut, alcohol, coal smoke, and salted fish Lancet Oncol 10 2009 1033 1034
13. J.L. Petrick, A.B. Wyss, A.M. Butler, and et al. Prevalence of human papillomavirus among oesophageal squamous cell carcinoma cases: systematic review and meta-analysis Br J Cancer 110 2014 2369 2377
14. H.A. Hardefeldt, M.R. Cox, and G.D. Eslick Association between human papillomavirus (HPV) and oesophageal squamous cell carcinoma: a meta-analysis Epidemiol Infect 142 2014 1119 1137
15. P.J. Brooks, M.A. Enoch, D. Goldman, and et al. The alcohol flushing response: an unrecognized risk factor for esophageal cancer from alcohol consumption PLoS Med 6 2009 e50
16. A. Yoshida, I.Y. Huang, and M. Ikawa Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in Orientals Proc Natl Acad Sci U S A 81 1984 258 261
17. H.W. Goedde, D.P. Agarwal, G. Fritze, and et al. Distribution of ADH2 and ALDH2 genotypes in different populations Hum Genet 88 1992 344 346
18. A. Yokoyama, E. Tsutsumi, H. Imazeki, and et al. Polymorphisms of alcohol dehydrogenase-1B and aldehyde dehydrogenase-2 and the blood and salivary ethanol and acetaldehyde concentrations of Japanese alcoholic men Alcohol Clin Exp Res 34 2010 1246 1256
19. M. Muto, M. Nakane, Y. Hitomi, and et al. Association between aldehyde dehydrogenase gene polymorphisms and the phenomenon of field cancerization in patients with head and neck cancer Carcinogenesis 23 2002 1759 1765
20. K. Matsuo, N. Hamajima, M. Shinoda, and et al. Gene-environment interaction between an aldehyde dehydrogenase-2 (ALDH2) polymorphism and alcohol consumption for the risk of esophageal cancer Carcinogenesis 22 2001 913 916
21. M. Uebelacker, and D.W. Lachenmeier Quantitative determination of acetaldehyde in foods using automated digestion with simulated gastric fluid followed by headspace gas chromatography J Autom Methods Manag Chem 2011 2011 907317
22. V.J. Salaspuro, J.M. Hietala, M.L. Marvola, and et al. Eliminating carcinogenic acetaldehyde by cysteine from saliva during smoking Cancer Epidemiol Biomarkers Prev 15 2006 146 149
23. G. Launoy, C. Milan, N.E. Day, and et al. Diet and squamous-cell cancer of the oesophagus: a French multicentre case-control study Int J Cancer 76 1998 7 12
24. N. Homann, H. Jousimies-Somer, K. Jokelainen, and et al. High acetaldehyde levels in saliva after ethanol consumption: methodological aspects and pathogenetic implications Carcinogenesis 18 1997 1739 1743
25. M.P. Salaspuro Acetaldehyde, microbes, and cancer of the digestive tract Crit Rev Clin Lab Sci 40 2003 183 208
26. M. Muto, Y. Hitomi, A. Ohtsu, and et al. Acetaldehyde production by non-pathogenic Neisseria in human oral microflora: implications for carcinogenesis in upper aerodigestive tract Int J Cancer 88 2000 342 350
27. H.K. Seitz, and F. Stickel Molecular mechanisms of alcohol-mediated carcinogenesis Nat Rev Cancer 7 2007 599 612
28. N.P. Singh, and A. Khan Acetaldehyde: genotoxicity and cytotoxicity in human lymphocytes Mutat Res 337 1995 9 17
29. P. Noori, and S.M. Hou Mutational spectrum induced by acetaldehyde in the HPRT gene of human T lymphocytes resembles that in the p53 gene of esophageal cancers Carcinogenesis 22 2001 1825 1830
30. A. Helander, and K. Lindahl-Kiessling Increased frequency of acetaldehyde-induced sister-chromatid exchanges in human lymphocytes treated with an aldehyde dehydrogenase inhibitor Mutat Res 264 1991 103 107
31. T. Matsuda, M. Kawanishi, T. Yagi, and et al. Specific tandem GG to TT base substitutions induced by acetaldehyde are due to intra-strand crosslinks between adjacent guanine bases Nucleic Acids Res 26 1998 1769 1774
32. A.J. Garro, N. Espina, F. Farinati, and et al. The effects of chronic ethanol consumption on carcinogen metabolism and on O6-methylguanine transferase-mediated repair of alkylated DNA Alcohol Clin Exp Res 10 1986 73S 77S
33. H.K. Seitz, and F. Stickel Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress Biol Chem 387 2006 349 360
34. R.A. Woutersen, L.M. Appelman, A. Van Garderen-Hoetmer, and et al. Inhalation toxicity of acetaldehyde in rats. III. Carcinogenicity study Toxicology 41 1986 213 231
35. V.J. Feron, A. Kruysse, and R.A. Woutersen Respiratory tract tumours in hamsters exposed to acetaldehyde vapour alone or simultaneously to benzo(a)pyrene or diethylnitrosamine Eur J Cancer Clin Oncol 18 1982 13 31
36. P.J. Brooks, and S. Zakhari Acetaldehyde and the genome: beyond nuclear DNA adducts and carcinogenesis Environ Mol Mutagen 55 2014 77 91
37. Y. Yukawa, S. Ohashi, Y. Amanuma, and et al. Impairment of aldehyde dehydrogenase 2 increases accumulation of acetaldehyde-derived DNA damage in the esophagus after ethanol ingestion Am J Cancer Res 4 2014 279 284
38. D.C. Upton, X. Wang, P. Blans, and et al. Replication of N2-ethyldeoxyguanosine DNA adducts in the human embryonic kidney cell line 293 Chem Res Toxicol 19 2006 960 967
39. J.A. Theruvathu, P. Jaruga, R.G. Nath, and et al. Polyamines stimulate the formation of mutagenic 1,N2-propanodeoxyguanosine adducts from acetaldehyde Nucleic Acids Res 33 2005 3513 3520
40. S. Stein, Y. Lao, I.Y. Yang, and et al. Genotoxicity of acetaldehyde- and crotonaldehyde-induced 1,N2-propanodeoxyguanosine DNA adducts in human cells Mutat Res 608 2006 1 7
41. V. Paget, M. Lechevrel, and F. Sichel Acetaldehyde-induced mutational pattern in the tumour suppressor gene TP53 analysed by use of a functional assay, the FASAY (functional analysis of separated alleles in yeast) Mutat Res 652 2008 12 19
42. S. Ishiguro, S. Sasazuki, M. Inoue, and et al. Effect of alcohol consumption, cigarette smoking and flushing response on esophageal cancer risk: a population-based cohort study (JPHC study) Cancer Lett 275 2009 240 246
43. D. Hoffmann, and S.S. Hecht Nicotine-derived N-nitrosamines and tobacco-related cancer: current status and future directions Cancer Res 45 1985 935 944
44. H. Bartsch, U. Nair, A. Risch, M. Rojas, H. Wikman, and K. Alexandrov Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers Cancer Epidemiol Biomarkers Prev 9 2000 3 28
45. Y. Nimura, S. Yokoyama, M. Fujimori, and et al. Genotyping of the CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking Cancer 80 1997 852 857
46. E.M. van Lieshout, H.M. Roelofs, S. Dekker, and et al. Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett's esophagus and esophageal carcinoma Cancer Res 59 1999 586 589
47. M.T. Wu, J.M. Lee, D.C. Wu, and et al. Genetic polymorphisms of cytochrome P4501A1 and oesophageal squamous-cell carcinoma in Taiwan Br J Cancer 87 2002 529 532
48. O. Moaven, H.R. Raziee, H.R. Sima, and et al. Interactions between Glutathione-S-transferase M1, T1 and P1 polymorphisms and smoking, and increased susceptibility to esophageal squamous cell carcinoma Cancer Epidemiol 34 2010 285 290
49. T. Hiyama, M. Yoshihara, S. Tanaka, and et al. Genetic polymorphisms and esophageal cancer risk Int J Cancer 121 2007 1643 1658
50. C.X. Yang, K. Matsuo, Z.M. Wang, and et al. Phase I/II enzyme gene polymorphisms and esophageal cancer risk: a meta-analysis of the literature World J Gastroenterol 11 2005 2531 2538
51. D. Hoffmann, and I. Hoffmann The changing cigarette, 1950-1995 J Toxicol Environ Health 50 1997 307 364
52. R. Cui, Y. Kamatani, A. Takahashi, and et al. Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk Gastroenterology 137 2009 1768 1775
53. F.T. Bosman, F. Carneiro, R.H. Hruban, and et al. WHO classification of tumours of the digestive system 2010 IARC Press Lyon, France
54. M. Mori, Y. Adachi, T. Matsushima, and et al. Lugol staining pattern and histology of esophageal lesions Am J Gastroenterol 88 1993 701 705
55. M. Muto, S. Hironaka, M. Nakane, and et al. Association of multiple Lugol-voiding lesions with synchronous and metachronous esophageal squamous cell carcinoma in patients with head and neck cancer Gastrointest Endosc 56 2002 517 521
56. D.P. Slaughter, H.W. Southwick, and W. Smejkal Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin Cancer 6 1953 963 968
57. F. Waridel, A. Estreicher, L. Bron, and et al. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract Oncogene 14 1997 163 169
58. M. Muto, M. Takahashi, A. Ohtsu, and et al. Risk of multiple squamous cell carcinomas both in the esophagus and the head and neck region Carcinogenesis 26 2005 1008 1012
59. L.H. Sobin, M.K. Gospodarowicz, and C. Wittekind Oesophagus including oesophagogastric junction. TNM classification of malignant tumours 7th ed. 2009 Wiley-Blackwell Oxford 66 72
60. S. Ohashi, M. Natsuizaka, S. Naganuma, and et al. A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors Cancer Res 71 2011 6836 6847
61. T. Nozoe, T. Oyama, M. Takenoyama, and et al. Significance of immunohistochemical expression of p27 and involucrin as the marker of cellular differentiation of squamous cell carcinoma of the esophagus Oncology 71 2006 402 410
62. Y. Song, L. Li, Y. Ou, Z. Gao, E. Li, X. Li, and et al. Identification of genomic alterations in oesophageal squamous cell cancer Nature 509 2014 91 95
63. D.C. Lin, J.J. Hao, Y. Nagata, L. Xu, and et al. Genomic and molecular characterization of esophageal squamous cell carcinoma Nat Genet 46 2014 467 473
64. Y.B. Gao, Z.L. Chen, J.G. Li, and et al. Genetic landscape of esophageal squamous cell carcinoma Nat Genet 46 2014 1097 1102
65. L. Zhang, Y. Zhou, C. Cheng, H. Cui, L. Cheng, P. Kong, J. Wang, Y. Lin, and et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma Am J Hum Genet 96 2015 597 611
66. W. Zhang, H. Zhu, X. Liu, and et al. Epidermal growth factor receptor is a prognosis predictor in patients with esophageal squamous cell carcinoma Ann Thorac Surg 98 2014 513 519
67. Z. Gao, X. Meng, D. Mu, and et al. Prognostic significance of epidermal growth factor receptor in locally advanced esophageal squamous cell carcinoma for patients receiving chemoradiotherapy Oncol Lett 7 2014 1118 1122
68. M.B. Burns, L. Lackey, M.A. Carpenter, and et al. APOBEC3B is an enzymatic source of mutation in breast cancer Nature 494 2013 366 370
69. S. Henderson, A. Chakravarthy, X. Su, and et al. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development Cell Rep 7 2014 1833 1841
70. T.D. Ahrens, M. Werner, and S. Lassmann Epigenetics in esophageal cancers Cell Tissue Res 356 2014 643 655
71. M. Zare, F.R. Jazii, M.R. Alivand, and et al. Qualitative analysis of Adenomatous Polyposis Coli promoter: hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker BMC Cancer 9 2009 24
72. C. Maesawa, G. Tamura, S. Nishizuka, and et al. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma Cancer Res 56 1996 3875 3878
73. Y. Ling, G. Huang, L. Fan, and et al. CpG island methylator phenotype of cell-cycle regulators associated with TNM stage and poor prognosis in patients with oesophageal squamous cell carcinoma J Clin Pathol 64 2011 246 251
74. N. Taghavi, F. Biramijamal, M. Sotoudeh, and et al. p16INK4a hypermethylation and p53, p16 and MDM2 protein expression in esophageal squamous cell carcinoma BMC Cancer 10 2010 138
75. D.C. Blaydon, S.L. Etheridge, J.M. Risk, and et al. RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome Am J Hum Genet 90 2012 340 346
76. R.S. Marger, and D. Marger Carcinoma of the esophagus and tylosis. A lethal genetic combination Cancer 72 1993 17 19
77. Y. Hong, X. Miao, X. Zhang, and et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma Cancer Res 65 2005 9582 9587
78. T. Sun, Y. Gao, W. Tan, and et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers Nat Genet 39 2007 605 613
79. Y. Guo, X. Zhang, W. Tan, and et al. Platelet 12-lipoxygenase Arg261Gln polymorphism: functional characterization and association with risk of esophageal squamous cell carcinoma in combination with COX-2 polymorphisms Pharmacogenet Genomics 17 2007 197 205
80. X. Yang, H. Zhu, Q. Qin, and et al. Genetic variants and risk of esophageal squamous cell carcinoma: a GWAS-based pathway analysis Gene 556 2015 149 152
81. C. Wu, Z. Wang, X. Song, and et al. Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations Nat Genet 46 2014 1001 1006
82. N.M. Lindor, M.L. McMaster, C.J. Lindor, and et al. Concise handbook of familial cancer susceptibility syndromes - second edition J Natl Cancer Inst Monogr 2008 1 93
83. G.L. Moldovan, and A.D. D'Andrea How the fanconi anemia pathway guards the genome Annu Rev Genet 43 2009 223 249
84. F. Langevin, G.P. Crossan, I.V. Rosado, and et al. Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice Nature 475 2011 53 58
85. M.R. Akbari, R. Malekzadeh, D. Nasrollahzadeh, and et al. Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma Oncogene 27 2008 1290 1296
86. J.A. DiPaolo, N.C. Popescu, L. Alvarez, and et al. Cellular and molecular alterations in human epithelial cells transformed by recombinant human papillomavirus DNA Crit Rev Oncog 4 1993 337 360
87. A.K. Adams, T.M. Wise-Draper, and S.I. Wells Human papillomavirus induced transformation in cervical and head and neck cancers Cancers (Basel) 6 2014 1793 1820
88. Y. Li, L. Fu, J.B. Li, and et al. Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma Gastroenterology 146 2014 1701 1713.e9
89. J. Kalabis, G.S. Wong, M.E. Vega, and et al. Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic culture Nat Protoc 7 2012 235 246
90. S. Ohashi, M. Natsuizaka, G.S. Wong, and et al. Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors Cancer Res 70 2010 4174 4184
91. T. Okawa, C.Z. Michaylira, J. Kalabis, and et al. The functional interplay between EGFR overexpression, hTERT activation, and p53 mutation in esophageal epithelial cells with activation of stromal fibroblasts induces tumor development, invasion, and differentiation Genes Dev 21 2007 2788 2803
92. K.D. Grugan, C.G. Miller, Y. Yao, and et al. Fibroblast-secreted hepatocyte growth factor plays a functional role in esophageal squamous cell carcinoma invasion Proc Natl Acad Sci U S A 107 2010 11026 11031
93. M. Natsuizaka, S. Ohashi, G.S. Wong, and et al. Insulin-like growth factor-binding protein-3 promotes transforming growth factor-{beta}1-mediated epithelial-to-mesenchymal transition and motility in transformed human esophageal cells Carcinogenesis 31 2010 1344 1353
94. C.Z. Michaylira, G.S. Wong, C.G. Miller, and et al. Periostin, a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer Cancer Res 70 2010 5281 5292
95. A. Long, V. Giroux, K.A. Whelan, and et al. WNT10A promotes an invasive and self-renewing phenotype in esophageal squamous cell carcinoma Carcinogenesis 36 2015 598 606
96. W.Q. Wei, Z.F. Chen, Y.T. He, and et al. Long-term follow-up of a community assignment, one-time endoscopic screening study of esophageal cancer in China J Clin Oncol 33 2015 1951 1957
97. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology: esophageal and esophagogastric junction cancers. Version.3.2015. 2015. Available at: http://www.nccn.org/professionals/physician-gls/pdf/esophageal.pdf.
98. Japan Esophageal Society Japanese classification of esophageal cancer, tenth edition: parts II and III Esophagus 6 2009 71 94
99. W. Schiller Early diagnosis of carcinoma of the cervix Surg Gynecol Obstet 56 1933 210 222
100. K. Sugimachi, K. Kitamura, K. Baba, and et al. Endoscopic diagnosis of early carcinoma of the esophagus using Lugol's solution Gastrointest Endosc 38 1992 657 661
101. Y. Shimizu, T. Omori, A. Yokoyama, and et al. Endoscopic diagnosis of early squamous neoplasia of the esophagus with iodine staining: high-grade intra-epithelial neoplasia turns pink within a few minutes J Gastroenterol Hepatol 23 2008 546 550
102. M. Muto, C. Katada, Y. Sano, and et al. Narrow band imaging: a new diagnostic approach to visualize angiogenesis in superficial neoplasia Clin Gastroenterol Hepatol 3 2005 S16 S20
103. M. Muto, K. Minashi, T. Yano, and et al. Early detection of superficial squamous cell carcinoma in the head and neck region and esophagus by narrow band imaging: a multicenter randomized controlled trial J Clin Oncol 28 2010 1566 1572
104. H. Inoue, M. Kaga, H. Ikeda, and et al. Magnification endoscopy in esophageal squamous cell carcinoma: a review of the intrapapillary capillary loop classification Ann Gastroenterol 28 2015 41 48
105. H. Makuuchi, H. Shimada, K. Mizutani, and et al. Endoscopic criteria for invasive depth of superficial esophageal cancer Dig Endosc 9 1997 110 115
106. K. Goda, H. Tajiri, M. Ikegami, and et al. Magnifying endoscopy with narrow band imaging for predicting the invasion depth of superficial esophageal squamous cell carcinoma Dis Esophagus 22 2009 453 460
107. M.S. Levine, P. Chu, E.E. Furth, and et al. Carcinoma of the esophagus and esophagogastric junction: sensitivity of radiographic diagnosis AJR Am J Roentgenol 168 1997 1423 1426
108. N. Thosani, H. Singh, A. Kapadia, and et al. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis Gastrointest Endosc 75 2012 242 253
109. J. Choi, S.G. Kim, J.S. Kim, and et al. Comparison of endoscopic ultrasonography (EUS), positron emission tomography (PET), and computed tomography (CT) in the preoperative locoregional staging of resectable esophageal cancer Surg Endosc 24 2010 1380 1386
110. S. Misra, M. Choi, A.S. Livingstone, and et al. The role of endoscopic ultrasound in assessing tumor response and staging after neoadjuvant chemotherapy for esophageal cancer Surg Endosc 26 2012 518 522
111. L.E. Quint, and N.R. Bogot Staging esophageal cancer Cancer Imaging 8 suppl A 2008 S33 S42
112. D. Picus, D.M. Balfe, R.E. Koehler, and et al. Computed tomography in the staging of esophageal carcinoma Radiology 146 1983 433 438
113. S. Takashima, N. Takeuchi, H. Shiozaki, and et al. Carcinoma of the esophagus: CT vs MR imaging in determining resectability AJR Am J Roentgenol 156 1991 297 302
114. E.P. van Vliet, M.H. Heijenbrok-Kal, M.G. Hunink, and et al. Staging investigations for oesophageal cancer: a meta-analysis Br J Cancer 98 2008 547 557
115. B.S. Kuszyk, D.A. Bluemke, B.A. Urban, and et al. Portal-phase contrast-enhanced helical CT for the detection of malignant hepatic tumors: sensitivity based on comparison with intraoperative and pathologic findings AJR Am J Roentgenol 166 1996 91 95
116. H.L. van Westreenen, M. Westerterp, P.M. Bossuyt, and et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer J Clin Oncol 22 2004 3805 3812
117. R.J. Downey, T. Akhurst, D. Ilson, and et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial J Clin Oncol 21 2003 428 432
118. R. Bar-Shalom, L. Guralnik, M. Tsalic, and et al. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer Eur J Nucl Med Mol Imaging 32 2005 918 924
119. W. Sureshbabu, and O. Mawlawi PET/CT imaging artifacts J Nucl Med Technol 33 2005 156 161 quiz 163-164
120. H. Kuwano, Y. Nishimura, T. Oyama, and et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society Esophagus 12 2015 1 30
121. M. Kodama, and T. Kakegawa Treatment of superficial cancer of the esophagus: a summary of responses to a questionnaire on superficial cancer of the esophagus in Japan Surgery 123 1998 432 439
122. A. Bhatt, S. Abe, A. Kumaravel, and et al. Indications and techniques for endoscopic submucosal dissection Am J Gastroenterol 110 2015 784 791
123. Y. Kurokawa, M. Muto, K. Minashi, and et al. A phase II trial of combined treatment of endoscopic mucosal resection and chemoradiotherapy for clinical stage I esophageal carcinoma: Japan Clinical Oncology Group Study JCOG0508 Jpn J Clin Oncol 39 2009 686 689
124. M.W. Wouters, G.A. Gooiker, J.W. van Sandick, and et al. The volume-outcome relation in the surgical treatment of esophageal cancer: a systematic review and meta-analysis Cancer 118 2012 1754 1763
125. T. Ye, Y. Sun, Y. Zhang, and et al. Three-field or two-field resection for thoracic esophageal cancer: a meta-analysis Ann Thorac Surg 96 2013 1933 1941
126. S.S. Biere, M.I. van Berge Henegouwen, K.W. Maas, and et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial Lancet 379 2012 1887 1892
127. K. Nagpal, K. Ahmed, A. Vats, and et al. Is minimally invasive surgery beneficial in the management of esophageal cancer? A meta-analysis Surg Endosc 24 2010 1621 1629
128. I. Ninomiya, K. Okamoto, T. Fujimura, and et al. Oncologic outcomes of thoracoscopic esophagectomy with extended lymph node dissection: 10-year experience from a single center World J Surg 38 2014 120 130
129. R.P. Merkow, K.Y. Bilimoria, M.D. McCarter, and et al. Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals Ann Surg Oncol 19 2012 357 364
130. M. Hingorani, T. Crosby, A. Maraveyas, and et al. Neoadjuvant chemoradiotherapy for resectable oesophageal and gastro-oesophageal junction cancer - do we need another randomised trial? Clin Oncol (R Coll Radiol) 23 2011 696 705
131. J.F. Bosset, M. Gignoux, J.P. Triboulet, and et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus N Engl J Med 337 1997 161 167
132. K.M. Sjoquist, B.H. Burmeister, B.M. Smithers, and et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis Lancet Oncol 12 2011 681 692
133. N. Ando, T. Iizuka, H. Ide, and et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study - JCOG9204 J Clin Oncol 21 2003 4592 4596
134. N. Ando, H. Kato, H. Igaki, and et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907) Ann Surg Oncol 19 2012 68 74
135. H. Hara, M. Tahara, H. Daiko, and et al. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma Cancer Sci 104 2013 1455 1460
136. K. Nakamura, K. Kato, H. Igaki, and et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study) Jpn J Clin Oncol 43 2013 752 755
137. M. Stahl, M. Stuschke, N. Lehmann, and et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus J Clin Oncol 23 2005 2310 2317
138. L. Bedenne, P. Michel, O. Bouche, and et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102 J Clin Oncol 25 2007 1160 1168
139. M. al-Sarraf, K. Martz, A. Herskovic, and et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study J Clin Oncol 15 1997 277 284
140. A. Ohtsu, N. Boku, K. Muro, and et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus J Clin Oncol 17 1999 2915 2921
141. K. Ishida, N. Ando, S. Yamamoto, and et al. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516) Jpn J Clin Oncol 34 2004 615 619
142. K. Kato, K. Muro, K. Minashi, and et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906) Int J Radiat Oncol Biol Phys 81 2011 684 690
143. A. Herskovic, K. Martz, M. al-Sarraf, and et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus N Engl J Med 326 1992 1593 1598
144. S.G. Swisher, P. Wynn, J.B. Putnam, and et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy J Thorac Cardiovasc Surg 123 2002 175 183
145. S. Ishikura, K. Nihei, A. Ohtsu, and et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus J Clin Oncol 21 2003 2697 2702
146. B.D. Minsky, T.F. Pajak, R.J. Ginsberg, and et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy J Clin Oncol 20 2002 1167 1174
147. R. Ishihara, S. Yamamoto, H. Iishi, and et al. Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy Int J Radiat Oncol Biol Phys 76 2010 123 129
148. C.H. Tu, M. Muto, T. Horimatsu, and et al. Submucosal tumor appearance is a useful endoscopic predictor of early primary-site recurrence after definitive chemoradiotherapy for esophageal squamous cell carcinoma Dis Esophagus 24 2011 274 278
149. H. Matsubara Salvage surgery for esophageal carcinoma after definitive chemoradiation therapy Ann Thorac Cardiovasc Surg 13 2007 293 295
150. T. Yano, M. Muto, S. Hattori, and et al. Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma Endoscopy 40 2008 717 721
151. T. Yano, M. Muto, K. Minashi, and et al. Photodynamic therapy as salvage treatment for local failures after definitive chemoradiotherapy for esophageal cancer Gastrointest Endosc 62 2005 31 36
152. B.M. Smithers, M. Cullinan, J.M. Thomas, and et al. Outcomes from salvage esophagectomy post definitive chemoradiotherapy compared with resection following preoperative neoadjuvant chemoradiotherapy Dis Esophagus 20 2007 471 477
153. M.Y. Homs, A. v d Gaast, P.D. Siersema, and et al. Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction Cochrane Database Syst Rev 2006 CD004063
154. J.A. Ajani, D.H. Ilson, K. Daugherty, and et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus J Natl Cancer Inst 86 1994 1086 1091
155. K. Muro, T. Hamaguchi, A. Ohtsu, and et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer Ann Oncol 15 2004 955 959
156. S. Hironaka, Y. Tsubosa, J. Mizusawa, and et al. Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807) Cancer Sci 105 2014 1189 2295
157. K. Kataoka, T. Tsushima, J. Mizusawa, and et al. A randomized controlled Phase III trial comparing 2-weekly docetaxel combined with cisplatin plus fluorouracil (2-weekly DCF) with cisplatin plus fluorouracil (CF) in patients with metastatic or recurrent esophageal cancer: rationale, design and methods of Japan Clinical Oncology Group study JCOG1314 (MIRACLE study) Jpn J Clin Oncol 45 2015 494 498
158. B. Burtness, M.A. Goldwasser, W. Flood, and et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study J Clin Oncol 23 2005 8646 8654
159. T. Crosby, C.N. Hurt, S. Falk, and et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial Lancet Oncol 14 2013 627 637
160. S.J. Dutton, D.R. Ferry, J.M. Blazeby, and et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial Lancet Oncol 15 2014 894 904
161. P. Sharma, and J.P. Allison The future of immune checkpoint therapy Science 348 2015 56 61
162. Y. Ohigashi, M. Sho, Y. Yamada, and et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer Clin Cancer Res 11 2005 2947 2953
163. J.M. Blazeby, M.H. Williams, S.T. Brookes, and et al. Quality of life measurement in patients with oesophageal cancer Gut 37 1995 505 508
164. R.J. Caspers, K. Welvaart, R.J. Verkes, and et al. The effect of radiotherapy on dysphagia and survival in patients with esophageal cancer Radiother Oncol 12 1988 15 23
165. Y. Dai, C. Li, Y. Xie, and et al. Interventions for dysphagia in oesophageal cancer Cochrane Database Syst Rev 10 2014 CD005048
166. D. Saranovic, A. Djuric-Stefanovic, A. Ivanovic, and et al. Fluoroscopically guided insertion of self-expandable metal esophageal stents for palliative treatment of patients with malignant stenosis of esophagus and cardia: comparison of uncovered and covered stent types Dis Esophagus 18 2005 230 238
167. E.A. Griffiths, C.J. Gregory, K.G. Pursnani, and et al. The use of biodegradable (SX-ELLA) oesophageal stents to treat dysphagia due to benign and malignant oesophageal disease Surg Endosc 26 2012 2367 2375
168. S. Lecleire, F. Di Fiore, E. Ben-Soussan, and et al. Prior chemoradiotherapy is associated with a higher life-threatening complication rate after palliative insertion of metal stents in patients with oesophageal cancer Aliment Pharmacol Ther 23 2006 1693 1702
169. J.H. Shin, H.Y. Song, G.Y. Ko, and et al. Esophagorespiratory fistula: long-term results of palliative treatment with covered expandable metallic stents in 61 patients Radiology 232 2004 252 259